APPH — Apontis Pharma AG Income Statement
0.000.00%
Last trade - 00:00- €93.30m
- €77.84m
- €48.47m
- 53
- 16
- 95
- 56
Annual income statement for Apontis Pharma AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | GAS | GAS | GAS | GAS | GAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 39.2 | 51.2 | 55.7 | 37 | 48.5 |
| Cost of Revenue | |||||
| Gross Profit | 25 | 33.8 | 35 | 23.2 | 27.7 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 39.9 | 50.5 | 51.9 | 52.1 | 47.2 |
| Operating Profit | -0.614 | 0.65 | 3.81 | -15.1 | 1.26 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.48 | 0.248 | 3.83 | -14.8 | 1.15 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.18 | -0.745 | 2.69 | -11.3 | 0.754 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.18 | -0.745 | 2.69 | -11.3 | 0.754 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.18 | -0.745 | 2.69 | -11.3 | 0.754 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.13 | 0.198 | 0.271 | -0.904 | 0.089 |
| Dividends per Share |